Can Bio-Thera’s BAT8013 turn regulatory T-cell depletion into a workable solid-tumor strategy?
Bio-Thera has dosed the first patient in BAT8013’s Phase 1 trial. See why safety, Treg selectivity and dose choice will decide its future.
Pharma & Biotech
Pharma & Biotech
Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.
Pharma & Biotech
Degron Therapeutics extends Series A as DEG6498 enters the harder phase of cancer drug validation
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
Pharma & Biotech
HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test
Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.
Pharma & Biotech
Can Forlong Biotechnology’s FL115 poster at ASCO 2026 move the IL-15 story from scientific promise toward clinical relevance?
Forlong Biotechnology brings FL115 to ASCO 2026 with first-in-human solid tumor data. Read why the IL-15 story could matter beyond the poster.
Pharma & Biotech
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.